About Relmada Therapeutics, Inc
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo in tested measures of depression. The Phase 2 study also showed a favorable safety, tolerability, and pharmacokinetics profile of REL-1017, consistent with results observed in the previously completed Phase 1 studies.
For media inquiries, please contact [email protected].
|
|
|
11-50 employees
View all Relmada Therapeutics, Inc employees
|
|
Pharmaceuticals
|
|
$10M–$50M
|
|
(212) 672-9100
|
|
2222 Ponce de Leon Blvd, Floor 3, Coral Gables, Florida 33134, US
|
|
2004
|
|
Chronic Pain, Pharmaceutical Development, Opioid Addiction, Analgesic Drug Development
|
Relmada Therapeutics, Inc Alternatives
Frequently Asked Questions about Relmada Therapeutics, Inc
Sergio Traversa is the CEO of Relmada Therapeutics, Inc. To contact Sergio Traversa email at [email protected] or [email protected]. Or you may call 8622029510 or +1.2128405442
The decision makers in Relmada Therapeutics, Inc are Andrea Varalli, Cornelia Kroeger, Cornelia Kroeger, etc. Click to Find Relmada Therapeutics, Inc decision makers emails.
Relmada Therapeutics, Inc headquarters is located at 2222 Ponce de Leon Blvd, Floor 3, Coral Gables, Florida 33134, US.
Relmada Therapeutics, Inc generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Relmada Therapeutics, Inc by calling (212) 672-9100.
Relmada Therapeutics, Inc Staff Directory
Search Relmada Therapeutics, Inc Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
